Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

21. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study (Abstract)

Association of statin use with spontaneous intracerebral hemorrhage: A cohort study To examine the association between statin exposure in a dose-dependent manner and intracerebral hemorrhage (ICH) in a large nationwide study.The computerized database of the largest health care provider in Israel was used to identify diagnosed ICH among new users of statins, who started statin treatment between 2005 and 2010. We assessed a dose-response relationship between ICH and statins, using the average (...) and robust among highly persistent statin users and after controlling for the change in cholesterol level.This study confirms that the risk of ICH decreases with increasing cholesterol levels, but suggests that statin use might be associated with decreased risk of ICH.© 2018 American Academy of Neurology.

2018 EvidenceUpdates

22. Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? (Abstract)

and the University of Toronto, Toronto, Canada. Electronic address: rob.hamilton@uhn.ca. eng Editorial Comment 2016 06 23 Netherlands Eur Urol Focus 101665661 2405-4569 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors EC 3.4.21.77 Prostate-Specific Antigen IM Eur Urol Focus. 2017 Apr;3(2-3):212-220 28753762 Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Male Prostate-Specific Antigen Prostatic Neoplasms 2016 05 30 2016 06 13 2017 7 30 6 0 2018 7 11 6 0 2017 7 30 6 0 ppublish 28753767 S2405-4569(16)30068-2 (...) Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 28753767 2018 07 10 2018 12 02 2405-4569 3 2-3 2017 04 European urology focus Eur Urol Focus Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 221-222 S2405-4569(16)30068-2 10.1016/j.euf.2016.06.008 Hamilton Robert J RJ Division of Urology, Departments of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network

2018 European urology focus Controlled trial quality: uncertain

23. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

24. Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Bailey Kent R KR Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Kullo Iftikhar J IJ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. eng Letter Pragmatic Clinical Trial Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA Cardiol 101676033 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors IM Aged Coronary Disease drug (...) therapy genetics Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Middle Aged 2016 7 21 6 0 2016 7 22 6 0 2018 6 27 6 0 ppublish 27438122 2513303 10.1001/jamacardio.2016.0227

2018 JAMA cardiology Controlled trial quality: uncertain

25. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy Full Text available with Trip Pro

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy Statins and/or PCSK9 inhibitors cause the regression of coronary atheroma and reduce clinical events. However, it currently remains unclear whether these drugs modulate coronary atheroma calcification in vivo. Coronary artery calcium (CAC) scores (Agatston Units, AUs) were estimated in 120 patients receiving coronary computed tomographic (...) angiography (CCTA) (63% males; median age 56 years). The CAC scores were compared among the three groups: (1) neither statin nor PCSK9 inhibitor therapy, (2) statin monotherapy, and (3) statin and PCSK9 inhibitor combination therapy in an unpaired cross-sectional study. Additionally, CCTA was performed twice at an interval in 15 patients undergoing statin monotherapy to compare the previous (baseline) and subsequent (follow-up) CAC scores in a paired longitudinal study. In addition, a PCSK9 inhibitor

2018 NPJ aging and mechanisms of disease

26. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial Full Text available with Trip Pro

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159).The UC options (no additional lipid-lowering (...) non-HDL cholesterol to a greater degree within each UC stratum at week 24. The incidence of treatment-emergent adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on glycated haemoglobin, or change in number of glucose-lowering agents, was seen.In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated.© 2018 The Authors. Diabetes, Obesity

2018 EvidenceUpdates

27. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study Full Text available with Trip Pro

Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study Diabetes is associated with high risk of cardiovascular (CV) events, particularly in patients with dyslipidemia and diabetic complications. We investigated the incidence of CV events with intensive or standard lipid-lowering therapy in patients with hypercholesterolemia, diabetic retinopathy, and no history of coronary artery disease (treat (...) -to-target approach).In this multicenter, prospective, randomized, open-label, blinded end point study, eligible patients were randomly assigned (1:1) to intensive statin therapy targeting LDL cholesterol (LDL-C) <70 mg/dL (n = 2,518) or standard statin therapy targeting LDL-C 100-120 mg/dL (n = 2,524).Mean follow-up was 37 ± 13 months. LDL-C at 36 months was 76.5 ± 21.6 mg/dL in the intensive group and 104.1 ± 22.1 mg/dL in the standard group (P < 0.001). The primary end point events occurred in 129

2018 EvidenceUpdates

28. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study Full Text available with Trip Pro

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).A retrospective cohort study and nested case-control study.The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.A cohort of 137 643 women over 40 years old and diagnosed (...) with T2D during 1996-2011 in Finland.In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti-diabetic medication or statins. In the nested case-control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration

2018 EvidenceUpdates

29. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 Full Text available with Trip Pro

Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to its ability to control cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective (...) and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favor of or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease.

2018 Journal of translational internal medicine

30. Lipid-lowering drugs (statins) and peripheral neuropathy Full Text available with Trip Pro

Lipid-lowering drugs (statins) and peripheral neuropathy Peripheral neuropathy is a disorder with often unknown causes. Some drugs, including statins, are proposed to be among the causes of peripheral neuropathy. This study aimed at evaluating this condition by electrodiagnostic study among patients who had received statins.This case-control study was conducted in Shiraz, Iran in 2015, and included 39 patients aged 35-55 who had received statins for at least 6 months, and 39 healthy matched (...) for one definition [2 abnormalities in 2 nerves (p=0.055)]. Regarding mean values of the features, significant differences were observed in two features: amplitude of the peroneal motor nerve (p=0.048) and amplitude of the sural sensory nerve (p=0.036).Since statins are widely used, awareness regarding their side-effects would lead to better treatment. Even though no significant differences were found between the groups regarding the occurrence of peripheral neuropathy, there were significant

2018 Electronic physician

31. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies Full Text available with Trip Pro

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs.Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein (...) particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study. The effect of statin therapy on lipid levels was evaluated in patients on statins at baseline and in patients who initiated statins during the study.Treatment with baricitinib was associated with increased levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides, but no significant change in LDL-C:HDL-C ratio. Lipid

2018 EvidenceUpdates

32. Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury Full Text available with Trip Pro

Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury Background and Aims: Acetaminophen (APAP) and HMG-CoA reductase inhibitors are common causes of drug-induced liver injury (DILI). This study aimed to determine the ability to reduce APAP- and statins-mediated liver injury by using formulations that combine glycosphingolipids and vitamin E. Methods: Mice were injected (...) with APAP or with statins and treated before and after with β-glucosylceramide (GC), with or without vitamin E. Mice were followed for changes in liver enzymes, liver histology, hepatic expression of JNK, STAT3 and caspase 3, as well as intrahepatic natural killer T cells (NKT) and the serum cytokine levels by flow cytometry. Results: Administration of GC before or after APAP alleviated the liver damage, as noted by a reduction of the liver enzymes, improvement in the liver histology and decreased

2018 Journal of clinical and translational hepatology

33. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. (Abstract)

Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Five major organizations recently published guidelines for using statins to prevent atherosclerotic cardiovascular disease (ASCVD): in 2013, the American College of Cardiology/American Heart Association (ACC/AHA); in 2014, the United Kingdom's National Institute for Health and Care Excellence (NICE); and in 2016, the Canadian Cardiovascular Society (CCS), the U.S. Preventive Services (...) Task Force (USPSTF), and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS).To compare the utility of these guidelines for primary prevention of ASCVD.Observational study of actual ASCVD events during 10 years, followed by a modeling study to estimate the effectiveness of different guidelines.The Copenhagen General Population Study.45 750 Danish persons aged 40 to 75 years who did not use statins and did not have ASCVD at baseline.The number of participants eligible

2018 Annals of Internal Medicine

34. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack Full Text available with Trip Pro

Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack Although there is no overall association between statin use and intracerebral hemorrhage (ICH), whether there is an increased risk among those with a history of ischemic stroke (IS) or transient ischemic attack (TIA) remains controversial. We evaluated the relationship of preadmission statin use with the risk of ICH in patients with a history of IS or TIA in a population-based (...) cohort.The Health Improvement Network primary care database in the United Kingdom was used to identify new users of low-dose aspirin and a matched comparison. Both cohorts were followed to identify incident cases of ICH, with validation by manual review of patient records and linkage to hospitalization data. In a nested case-control study, we compared the adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for ICH based on statin use in the subgroup of individuals with history of IS/TIA.Last

2018 EvidenceUpdates

35. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Full Text available with Trip Pro

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition

2018 EvidenceUpdates

36. Primary care: Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis Full Text available with Trip Pro

, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov, and Web of Knowledge conference abstracts, and limited the search from earliest available to December 2017. The MEDLINE search strategy was: (1) randomised controlled trial (pt); (2) controlled clinical trial (pt); (3) randomised (tiab); (4) clinical trial (all); (5) randomly (tiab); (6) trial (ti); (7) placebo (ti); (8) 1 or 2 or 3 or 4 or 5 or 6 or 7; (9) hypolipidaemic agents (mesh); (10) hydroxymethylglutaryl-CoA reductase (...) inhibitors (mesh); (11) statin (tw); (12) 9 or 10 or 11; (13) antihypertensive agents (mesh); (14) cardiovascular (all); (15) cardiovascular diseases (majr); (16) 14 or 15; (17) 8 and 12 and 13 and 16. Similar search strategies were applied to the other sources. Reference lists of relevant publications were hand searched. Study selection Studies were included in the systematic review if they were factorial and had at least two randomised interventions, had a total duration of at least 100 patient-years

2018 Evidence-Based Medicine

37. Are statins beneficial for the treatment of pulmonary hypertension? Full Text available with Trip Pro

Are statins beneficial for the treatment of pulmonary hypertension? Pulmonary hypertension (PH) is a condition characterized by vasoconstriction and vascular remodeling with a poor prognosis. The current medical treatments available are supportive care therapy and pulmonary vascular-targeted therapy. Targeted treatments for PH include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors; however, these treatments cannot reverse pulmonary vascular (...) remodeling. Recently, many novel treatment options involving drugs such as statins have been emerging. In this review, we attempt to summarize the current knowledge of the role of statins in PH treatment and their potential clinical effects. Many basic researches have proved that statins can be helpful for the treatment of PH both in vitro and in experimental models. The main mechanisms underlying the effects of statins are restoration of endothelial function, attenuation of pulmonary vascular remodeling

2017 Chronic diseases and translational medicine

38. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient) Full Text available with Trip Pro

Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient) Several studies suggested that statins during hospitalization were associated with better disability outcomes in patients with acute ischemic stroke, but only 1 small randomized trial is available.We conducted a multicenter, open-label, randomized controlled trial in patients with acute ischemic strokes in 11 (...) hospitals in Japan. Patients with acute ischemic stroke and dyslipidemia randomly received statins within 24 hours after admission in the early group or on the seventh day in the delayed group, in a 1:1 ratio. Statins were administered for 12 weeks. The primary outcome was patient disability assessed by modified Rankin Scale at 90 days.A total of 257 patients were randomized and analyzed (early 131, delayed 126). At 90 days, modified Rankin Scale score distribution did not differ between groups (P=0.68

2017 EvidenceUpdates

39. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Full Text available with Trip Pro

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL (...) atherosclerotic cardiovascular disease currently receiving statin. Patients were classified by a baseline LDL-C of less than 70 or at least 70 mg/dL and by statin intensity (maximal: atorvastatin calcium, 80 mg/d, or rosuvastatin, 40 mg/d; submaximal: all other dosages). Patients with baseline LDL of less than 70 mg/dL either had a final screening LDL-C of at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 100 mg/dL. Data were retrieved from 2013 to 2016

2017 JAMA cardiology Controlled trial quality: predicted high

40. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Full Text available with Trip Pro

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated in adolescents.We (...) screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion, assessed according

2017 NEJM Controlled trial quality: predicted high